The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of pembrolizumab (pembro) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after progression on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on immune re-sensitization.
 
Yan Xu
No Relationships to Disclose
 
Minjiang Chen
No Relationships to Disclose
 
Xiaoxing Gao
No Relationships to Disclose
 
Xiaoyan Liu
No Relationships to Disclose
 
Jing Zhao
No Relationships to Disclose
 
Wei Zhong
No Relationships to Disclose
 
RuiLi Pan
No Relationships to Disclose
 
Mengzhao Wang
No Relationships to Disclose